Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

Inclusion Criteria:

1. Healthy male or female infant ≥42 days to ≤89 days (inclusive).

2. Full-term infant at least 37 weeks gestational age at birth.

3. Afebrile for ≥72 hours with a rectal temperature <38.0°C (<100.4°F) or axillarytemperature <37.8°C (<100.0°F) before receipt of study vaccine.*

4. Able to attend all scheduled visits and comply with the study procedures.

5. Subject's parent/legal guardian is able to read and understands the studyprocedures, alternate treatments, risks and benefits, and provides written informedconsent.

6. Subject's parent/legal guardian is able to fill out an ediary of solicited AE andtake daily axillary temperature and measurements of local injection site reactionsfor the 7 days after each study vaccination.

7. Subject's parent/legal guardian has an e-mail address and access to a computer orsmartphone with internet to complete the ediary.

Exclusion Criteria:

1. History of invasive pneumococcal disease (positive blood culture, positivecerebrospinal fluid culture, or other sterile site) or known history of otherculture positive pneumococcal disease.

2. Previous receipt of a licensed or investigational vaccine (excluding 1 dosehepatitis B vaccine).

3. Known hypersensitivity to any vaccine.

4. Known or suspected impairment of immunological function (e.g., asplenia, HIV,primary immunodeficiency).

5. Use of any immunosuppressive therapy (Note: topical and inhaled/nebulized steroidsare permitted).

6. History of failure to thrive.

7. Subject has a coagulation disorder contraindicating IM vaccination.

8. Subject or his/her mother have documented hepatitis B surface antigen-positive.

9. Has a known neurologic or cognitive behavioral disorder.

10. Has a known clinically significant congenital malformation or serious chronicdisorder.

11. Receipt of a blood transfusion or blood products, including immunoglobulins.

12. Receipt of any investigational study product since birth, currently participating inanother interventional investigational study, or having plans to receive anotherinvestigational product(s) while on study.

13. Any infant who cannot be adequately followed for safety according to the protocolplan.

14. Any other reason that in the opinion of the investigator may interfere with theevaluation required by the study.